CN100413835C - 抑制hiv tat反式激活作用的化合物 - Google Patents

抑制hiv tat反式激活作用的化合物 Download PDF

Info

Publication number
CN100413835C
CN100413835C CNB2005100743359A CN200510074335A CN100413835C CN 100413835 C CN100413835 C CN 100413835C CN B2005100743359 A CNB2005100743359 A CN B2005100743359A CN 200510074335 A CN200510074335 A CN 200510074335A CN 100413835 C CN100413835 C CN 100413835C
Authority
CN
China
Prior art keywords
cells
hiv
ndga
seap
tat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2005100743359A
Other languages
English (en)
Chinese (zh)
Other versions
CN1762951A (zh
Inventor
R·C·黄
J·N·格纳布里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CN1762951A publication Critical patent/CN1762951A/zh
Application granted granted Critical
Publication of CN100413835C publication Critical patent/CN100413835C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
CNB2005100743359A 1994-09-30 1995-09-22 抑制hiv tat反式激活作用的化合物 Expired - Fee Related CN100413835C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/316,341 1994-09-30
US08/316,341 US6365787B1 (en) 1994-09-30 1994-09-30 Compounds for the suppression of HIV TAT transactivation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB951960350A Division CN1211335C (zh) 1994-09-30 1995-09-22 抑制hivtat反式激活作用的化合物

Publications (2)

Publication Number Publication Date
CN1762951A CN1762951A (zh) 2006-04-26
CN100413835C true CN100413835C (zh) 2008-08-27

Family

ID=23228649

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB2005100743359A Expired - Fee Related CN100413835C (zh) 1994-09-30 1995-09-22 抑制hiv tat反式激活作用的化合物
CNB951960350A Expired - Fee Related CN1211335C (zh) 1994-09-30 1995-09-22 抑制hivtat反式激活作用的化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB951960350A Expired - Fee Related CN1211335C (zh) 1994-09-30 1995-09-22 抑制hivtat反式激活作用的化合物

Country Status (10)

Country Link
US (4) US6365787B1 (enExample)
EP (1) EP0783474B1 (enExample)
JP (2) JP3966900B2 (enExample)
CN (2) CN100413835C (enExample)
AT (1) ATE403635T1 (enExample)
AU (1) AU700481B2 (enExample)
CA (1) CA2200991C (enExample)
DE (1) DE69535804D1 (enExample)
ES (1) ES2312168T3 (enExample)
WO (1) WO1996010549A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365787B1 (en) * 1994-09-30 2002-04-02 The Johns Hopkins University Compounds for the suppression of HIV TAT transactivation
WO1999017609A1 (en) * 1997-10-07 1999-04-15 Larreacorp, Ltd. Nontoxic extract of larrea tridentata and method of making the same
US6608108B2 (en) * 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
US20030219407A1 (en) 2002-05-15 2003-11-27 The Regents Of The University Of California RNA silencing in animals as an antiviral defense
US7728036B2 (en) * 2003-05-20 2010-06-01 Erimos Pharmaceuticals, Llc Methods for delivery of catecholic butanes for treatment of tumors
CN103585136A (zh) * 2003-05-20 2014-02-19 约翰霍普金斯大学 用于治疗肿瘤的邻苯二酚丁烷的释放的方法和组合物
US20060141029A1 (en) * 2003-05-20 2006-06-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases
CN100440843C (zh) * 2004-05-12 2008-12-03 华为技术有限公司 一种环网及其业务实现方法
US8440648B2 (en) * 2004-07-20 2013-05-14 Erimos Pharmaceuticals Llc Methods and compositions for treatment of intraepithelial neoplasia
CN101150956B (zh) * 2005-01-27 2013-04-17 埃里莫斯医药品有限公司 用于注射入动物的包括ndga化合物的儿茶酚丁烷配方
WO2006081363A2 (en) * 2005-01-27 2006-08-03 Erimos Pharmaceuticals Llc Oral formulations for delivery of catecholic butanes including ndga compounds
KR20090006062A (ko) * 2006-02-23 2009-01-14 에리모스 파마슈티컬스 엘엘씨 인플루엔자 바이러스 감염의 치료 방법
EP2076252B1 (en) * 2006-10-02 2014-04-02 Erimos Pharmaceuticals LLC Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
US9067875B2 (en) 2006-10-02 2015-06-30 Erimos Pharmaceuticals Llc Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
HRP20161017T1 (hr) * 2007-05-11 2016-10-21 Convatec Technologies Inc. Ostomijski uređaj
US20100093872A1 (en) * 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
MX2011004824A (es) * 2008-11-07 2012-01-12 Triact Therapeutics Inc Uso de derivados de butano catecólico en terapia contra el cáncer.
EP2663574A4 (en) * 2011-01-10 2014-12-17 Scripps Research Inst RETRO VIRUS REPLICATION INHIBITORS
SG11201404542TA (en) * 2012-02-03 2014-10-30 Univ Johns Hopkins Compositions comprising ndga derivatives and sorafenib and their use in treatment of cancer
SG11201500397XA (en) * 2012-07-18 2015-03-30 Univ Johns Hopkins Methods for inhibition of bnip3 and prevention and treatment of ischemia reperfusion injury by tetra-o-methyl nordihydroguaiaretic acid
US9834575B2 (en) 2013-02-26 2017-12-05 Triact Therapeutics, Inc. Cancer therapy
EP3044593A4 (en) 2013-09-09 2017-05-17 Triact Therapeutics, Inc. Cancer therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003026A1 (en) * 1986-10-28 1988-05-05 Chemex Pharmaceuticals, Inc. Compositions of catecholic butanes with zinc

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008294A (en) 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes
US5276060A (en) * 1979-06-19 1994-01-04 Block/Chemex, G.P. Methods of treating tumors with compositions of catecholic butanes
DE3009542A1 (de) 1980-03-13 1981-09-24 Henkel KGaA, 4000 Düsseldorf Desodorierende kosmetische zusammensetzungen
US4774229A (en) 1982-04-05 1988-09-27 Chemex Pharmaceuticals, Inc. Modification of plant extracts from zygophyllaceae and pharmaceutical use therefor
FR2632956B2 (fr) * 1988-05-13 1991-07-12 Pasteur Institut Sondes a papillomavirus hpv49, hpv50, hpv54, hpv55; produits genetiquement et immunologiquement lies a ce papillomavirus hpv49, hpv50, hpv54, hpv55; procede de diagnostic in vitro d'infections a papillomavirus et d'immunisation in vivo contre ces papillomavirus
US5559149A (en) 1990-01-29 1996-09-24 Johnson & Johnson Consumer Products, Inc. Skin care compositions containing retinoids
US5195965A (en) * 1991-03-07 1993-03-23 Shantha Totada R Method and apparatus for localized treatment of human viral infections and cancers
US5646186A (en) 1994-05-17 1997-07-08 Johnson & Johnson Consumer Products, Inc. Retinoid composition
US5409690A (en) * 1993-06-23 1995-04-25 Chemex Pharmaceuticals, Inc. Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol
US6365787B1 (en) * 1994-09-30 2002-04-02 The Johns Hopkins University Compounds for the suppression of HIV TAT transactivation
US6071949A (en) 1995-03-14 2000-06-06 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
US5837252A (en) * 1996-07-01 1998-11-17 Larreacorp, Ltd. Nontoxic extract of Larrea tridentata and method of making same
US5827898A (en) 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes
US6245523B1 (en) 1996-11-20 2001-06-12 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
US6214874B1 (en) * 1999-10-15 2001-04-10 John Hopkins University Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N
US6608108B2 (en) * 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003026A1 (en) * 1986-10-28 1988-05-05 Chemex Pharmaceuticals, Inc. Compositions of catecholic butanes with zinc

Also Published As

Publication number Publication date
US5663209A (en) 1997-09-02
US6365787B1 (en) 2002-04-02
JP2006273869A (ja) 2006-10-12
DE69535804D1 (de) 2008-09-18
USRE40246E1 (en) 2008-04-15
AU700481B2 (en) 1999-01-07
JP3966900B2 (ja) 2007-08-29
EP0783474B1 (en) 2008-08-06
CA2200991C (en) 2007-07-10
CN1762951A (zh) 2006-04-26
EP0783474A1 (en) 1997-07-16
ES2312168T3 (es) 2009-02-16
JPH10509421A (ja) 1998-09-14
ATE403635T1 (de) 2008-08-15
US6291524B1 (en) 2001-09-18
AU3633995A (en) 1996-04-26
WO1996010549A1 (en) 1996-04-11
CN1211335C (zh) 2005-07-20
CN1162301A (zh) 1997-10-15
EP0783474A4 (enExample) 1997-08-27
CA2200991A1 (en) 1996-04-11

Similar Documents

Publication Publication Date Title
CN100413835C (zh) 抑制hiv tat反式激活作用的化合物
Gnabre et al. Isolation of anti-HIV-1 lignans from Larrea tridentata by counter-current chromatography
WO1996010549A9 (en) Compounds for the suppression of hiv tat transactivation
KR101567633B1 (ko) 감귤 미성숙과 추출물, 또는 시네프린 또는 이의 염을 유효성분으로 포함하는 염증성 피부질환 치료 또는 예방용 조성물
GB2450190A (en) Cyclohexenones from Antrodia Camphorata for use in the treatment of autoimmune disease
US10143673B2 (en) Active fraction of a polar solvent extract from the latex of euphorbiaceae plants
US20110086872A1 (en) Berberine as a selective lung cancer agent and other compositions and methods
CN111558007B (zh) 一种玉米根提取物及其制备方法和应用
US5989555A (en) Extracts of Larrea tridentata having antiviral activity and their use for treating viral infections
HK1090023A (en) Compounds for the suppression of hiv tat transactivation
CN110452122B (zh) 庚烯二酸二甲酯类化合物及其制备方法和应用
HK1124526A (en) Active fraction of a polar solvent extract from the latex of euphorbiaceae plants
JPH07112931A (ja) エプスタイン−バーウイルス活性化抑制剤
CN101257912A (zh) 大戟科植物乳汁的极性溶剂提取物的活性级份
CN118344432A (zh) 环肽生物碱类化合物及其制备方法和应用
Kagunya Phytochemical and Toxicological Evaluation of Croton Menyharthii From Tana River County, Kenya
DE19908766C2 (de) Verwendung synthetischer Vpr-Peptide des Humanen Immundefizienzvirus Typ 1 (HIV-1) zur Entwicklung von therapeutischen und diagnostischen Reagenzien
AU2005202105B2 (en) Biologically active aqueous fraction of an extract obtained from a mangrove plant Salvadora Persica L.
Plants Fidelia Ijeoma Uche

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1090023

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080827

Termination date: 20091022

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1090023

Country of ref document: HK